CymaBay up on completing enrollment in key liver disease therapy study

CymaBay Therapeutics

01/08/2022 17:02

** Shares of CymaBay Therapeutics Inc  CBAY.O  rise 6.7% to
$3.34
    ** CBAY says it completed patient enrollment in a global
late-stage study evaluating its drug candidate, seladelpar, for
the treatment of a chronic liver disease  urn:newsml:reuters.com:*:nGNX1wgtKF
    ** Co is testing the drug among patients with primary
biliary cholangitis (PBC) who have received prior therapy
    ** PBC is a disease in which small bile ducts in the liver
become inflamed, which could eventually cause liver damage
    ** CBAY shares rose in July for the second straight month
    ** Stock down about 1% YTD, including session gains

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))